Your shopping cart is currently empty

CPA 926 is an orally active prodrug of Esculetin that inhibits the production of MMP in cartilage explants. It is applicable for inflammation research, including studies on experimental osteoarthritis.
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | CPA 926 is an orally active prodrug of Esculetin that inhibits the production of MMP in cartilage explants. It is applicable for inflammation research, including studies on experimental osteoarthritis. |
| In vivo | CPA 926 (200-400 mg/kg, oral administration, once daily for 14 days) has been shown to inhibit cartilage degradation in experimental osteoarthritis in rabbits. |
| Molecular Weight | 381.34 |
| Formula | C17H19NO9 |
| Cas No. | 169673-60-3 |
| Smiles | O([C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C=2C=C3C(=CC2O)OC(=O)C=C3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.